Pharmacokinetics and Antitumor Efficacy of XMT-1001, a Novel, Polymeric Topoisomerase I Inhibitor, in Mice Bearing HT-29 Human Colon Carcinoma Xenografts - Bertin Instruments

    Scientific publications

    Pharmacokinetics and Antitumor Efficacy of XMT-1001, a Novel, Polymeric Topoisomerase I Inhibitor, in Mice Bearing HT-29 Human Colon Carcinoma Xenografts

    1. Mark D Walsh1, 2. Suzan K Hanna1, 3. Jeremy M Sen1, 4. Sumit Rawal2, 5. Carolina B Cabral3, 6. Aleksandr V Yurkovetskiy4, 7. Robert J Fram3, 8. Timothy B Lowinger3, and 9. William C Zamboni5,*
    Sources: 1. 1UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill (UNC) 2. 2UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill 3. 3Mersana Therapeutics, Inc. 4. 4Chemistry, Mersana Therapeutics, Inc. 5. 5University of North Carolina at Chapel Hill, School of Pharmacy 1. ↵* Corresponding Author: William C Zamboni, University of North Carolina at Chapel Hill, School of Pharmacy, Genetic Medicine Building, Room 1013, CB# 7361, 120 Mason Farm Road, Chapel Hill, NC, 27599, United States zamboni@unc.edu
    Clinical Cancer research,. Published OnlineFirst March 5, 2012; doi: 10.1158/1078-0432.CCR-11-1554

    Sample name

    Animal tissues (mice)

    ANY QUESTIONS? CONTACT AN EXPERT

    Please fill in this form if you wish to contact our sales team or receive further information.

    My Account
    Forgot password ?

    Add a question !

    Add a question